热门资讯> 正文

Trevi Therapeutics任命新首席财务官

2025-12-04 20:43

Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026.
Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte.
Hastings currently serves on the board and chairs the audit committee of Scynexis.

More on Trevi Therapeutics

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Trevi Therapeutics edges higher amid takeover speculation
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。